20160128 PR transgene BEI final version
Category: Press release
Transgene Announces Financial Calendar for 2016
20160108 financial calendar_EN ver 1
Transgene enters new phase in its strategic development
20160107 Strategic update ENG clean
Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
20160106 Ph 3 pexa vec in HCC trial initiation VER8
Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
20151223_TIME Ph2b Lancet Oncology 2015_PR EN
Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
20151112 SillaJen_Pexavec_Joint
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
20151103 TG1050 FINAL VERSION US
Transgene Reports Third Quarter 2015 Financial Results
20151021 PR US Q3 2015 FINAL
Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
23092015 PR ladenburg conf_EN
Transgene Reports Financial Results for First Six Months of 2015 (interim report)
20150910 – PR 2015 H1 results final
